ZA201100014B - Piperazine derivatives used as cav2.2 calcium channel modulators - Google Patents

Piperazine derivatives used as cav2.2 calcium channel modulators

Info

Publication number
ZA201100014B
ZA201100014B ZA2011/00014A ZA201100014A ZA201100014B ZA 201100014 B ZA201100014 B ZA 201100014B ZA 2011/00014 A ZA2011/00014 A ZA 2011/00014A ZA 201100014 A ZA201100014 A ZA 201100014A ZA 201100014 B ZA201100014 B ZA 201100014B
Authority
ZA
South Africa
Prior art keywords
calcium channel
derivatives used
piperazine derivatives
channel modulators
modulators
Prior art date
Application number
ZA2011/00014A
Other languages
English (en)
Inventor
Paul John Beswick
Alister Campbell
Andrew Peter Cridland
Robert James Gleave
Jag Paul Heer
Neville Hubert Nicholson
Lee William Page
Sadie Vile
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Publication of ZA201100014B publication Critical patent/ZA201100014B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2011/00014A 2008-07-17 2011-01-03 Piperazine derivatives used as cav2.2 calcium channel modulators ZA201100014B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0813142.7A GB0813142D0 (en) 2008-07-17 2008-07-17 Novel compounds
PCT/EP2009/059012 WO2010007073A1 (en) 2008-07-17 2009-07-15 Piperazine derivatives used as cav2.2 calcium channel modulators

Publications (1)

Publication Number Publication Date
ZA201100014B true ZA201100014B (en) 2011-09-28

Family

ID=39737239

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/00014A ZA201100014B (en) 2008-07-17 2011-01-03 Piperazine derivatives used as cav2.2 calcium channel modulators

Country Status (19)

Country Link
US (3) US8288388B2 (enExample)
EP (2) EP2300432B1 (enExample)
JP (2) JP5543966B2 (enExample)
KR (1) KR101599087B1 (enExample)
CN (1) CN102099337B (enExample)
AR (1) AR072809A1 (enExample)
AU (1) AU2009272762B2 (enExample)
BR (1) BRPI0916622A2 (enExample)
CA (1) CA2730471C (enExample)
EA (1) EA018621B1 (enExample)
ES (2) ES2396962T3 (enExample)
GB (1) GB0813142D0 (enExample)
IL (1) IL210446A (enExample)
MX (1) MX2011000600A (enExample)
PL (1) PL2300432T3 (enExample)
TW (1) TW201016677A (enExample)
UY (1) UY31990A (enExample)
WO (2) WO2010007072A1 (enExample)
ZA (1) ZA201100014B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
JP6058556B2 (ja) * 2011-01-19 2017-01-11 クオンベルゲンセ プハルマセウトイカルス リミテッド ＣａＶ２．２カルシウムチャンネルブロッカーとしてのピペラジン誘導体
MX345873B (es) 2011-06-27 2017-02-21 Newron Pharm Spa Derivados de arilalquilaminocarboxamida fluorados.
WO2015158426A1 (en) * 2014-04-14 2015-10-22 Grünenthal GmbH Aryl substituted heterocyclyl sulfones
AR100073A1 (es) * 2014-04-14 2016-09-07 Gruenenthal Gmbh Sulfonas heterocíclicas sustituidas con heteroarilos
GB201516183D0 (en) * 2015-09-14 2015-10-28 Calchan Ltd Novel pharmaceutical composition
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
SG10202111885PA (en) * 2017-04-26 2021-12-30 Cavion Inc Methods for improving memory and cognition and for treating memory and cognitive disorders
CN118085389B (zh) * 2024-03-11 2024-11-05 伟建实业(苏州)有限公司 一种环保型抗菌海绵及其制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006371A1 (fr) 1987-02-13 1988-08-25 Mitsubishi Denki Kabushiki Kaisha Demarreur/chargeur pour moteurs
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5498711A (en) 1993-02-03 1996-03-12 Thiokol Corporation Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1996025405A1 (en) 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
AU5432696A (en) 1995-04-07 1996-10-23 Pharmacopeia, Inc. Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
FR2744450A1 (fr) 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ATE233743T1 (de) 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
JP4024309B2 (ja) 1996-10-22 2007-12-19 第一三共株式会社 新規な感染症治療薬
GB9623283D0 (en) 1996-11-08 1997-01-08 Zeneca Ltd Heterocyclic derivatives
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
EP0986551B1 (en) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Sulfonamide derivatives, their production and use
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EE04617B1 (et) 1997-09-05 2006-04-17 Glaxo Group Limited 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
BR9913654A (pt) 1998-08-28 2001-11-27 Scios Inc Inibidores de p-38alfa quinase
NZ511349A (en) 1998-11-03 2003-10-31 Glaxo Group Ltd Pyrazolopyridine derivatives useful as selective COX-2 inhibitors
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
ES2216631T3 (es) 1999-02-27 2004-10-16 Glaxo Group Limited Pirazolpiridinas.
GB9927844D0 (en) 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
WO2001064676A2 (en) 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US20040110764A1 (en) 2000-04-10 2004-06-10 Stump Craig A. Inhibitors of prenyl-protein transferase
FR2812198B1 (fr) 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
JP4365102B2 (ja) 2001-04-26 2009-11-18 コーロン ライフ サイエンス インク 新規なスルホンアミド誘導体、その中間体化合物、及びその製造方法、並びにスルホンアミド誘導体を含む薬剤学的組成物
DE10155684A1 (de) 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
AR040405A1 (es) 2002-04-18 2005-04-06 Schering Corp Derivados de bencimidazol utiles como antagonistas de histamina h3
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
DE10319435B4 (de) * 2003-04-25 2018-07-26 Whitecryption Corporation Verfahren zur Verarbeitung von Daten zum Schutz eines Softwareprogramms vor Rekonstruktion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050277629A1 (en) 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
JP2007538106A (ja) 2004-05-20 2007-12-27 イーラン ファーマスーティカルズ、インコーポレイテッド γセクレターゼのＮ−環式スルホンアミド阻害剤
DE102004035672A1 (de) 2004-07-22 2006-03-30 Windmöller & Hölscher Kg Verkürzte Stapelbildung
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
DE102004054053A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2009519349A (ja) 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
AU2006331850A1 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
WO2007075524A2 (en) 2005-12-22 2007-07-05 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
BRPI0621027A2 (pt) 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
WO2007103456A2 (en) 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
US7524848B2 (en) * 2006-03-23 2009-04-28 Amgen Inc. Diaza heterocyclic amide compounds and their uses
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
EP2056828A4 (en) 2006-08-21 2010-06-23 Merck Sharp & Dohme SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008075019A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Modulators of cb1 receptors
US7648979B2 (en) 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
WO2008150447A1 (en) 2007-05-31 2008-12-11 Euro-Celtique S.A. Amide compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8304434B2 (en) 2007-10-04 2012-11-06 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EP2346828B1 (en) 2012-10-03
CN102099337A (zh) 2011-06-15
AR072809A1 (es) 2010-09-22
EA018621B1 (ru) 2013-09-30
GB0813142D0 (en) 2008-08-27
JP5688850B2 (ja) 2015-03-25
EA201170209A1 (ru) 2011-08-30
US20110130379A1 (en) 2011-06-02
UY31990A (es) 2010-01-05
US20100022555A1 (en) 2010-01-28
AU2009272762B2 (en) 2013-08-15
JP2011528020A (ja) 2011-11-10
WO2010007073A1 (en) 2010-01-21
ES2396962T3 (es) 2013-03-01
TW201016677A (en) 2010-05-01
US8536183B2 (en) 2013-09-17
KR101599087B1 (ko) 2016-03-02
US8288388B2 (en) 2012-10-16
AU2009272762A1 (en) 2010-01-21
MX2011000600A (es) 2011-05-24
CN102099337B (zh) 2013-08-21
CA2730471A1 (en) 2010-01-21
WO2010007072A1 (en) 2010-01-21
EP2300432A1 (en) 2011-03-30
US20120302746A1 (en) 2012-11-29
IL210446A0 (en) 2011-03-31
IL210446A (en) 2014-01-30
JP2011528019A (ja) 2011-11-10
KR20110031199A (ko) 2011-03-24
ES2396960T3 (es) 2013-03-01
JP5543966B2 (ja) 2014-07-09
US8530478B2 (en) 2013-09-10
PL2300432T3 (pl) 2013-03-29
EP2346828A1 (en) 2011-07-27
EP2300432B1 (en) 2012-10-03
CA2730471C (en) 2016-12-06
BRPI0916622A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
IL210446A0 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
ZA200908883B (en) Sirtuin modulating compounds
IL212969A0 (en) Tgr5 modulator compounds, compositions comprising the same and uses thereof
IL213787A0 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
IL202729A0 (en) Sirtuin modulating imidazothiazole compounds
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
GB0809360D0 (en) Calcium modulation
ZA201001157B (en) Sulfonamides as trpm8 modulators
IL225694A0 (en) Compounds 6,5- dihydro-h1-pyridine-2-one
EP2282735A4 (en) COMPOUNDS, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
IL202284A0 (en) Kallikrein 7 modulators
ZA200801744B (en) 1,2-Diarylimidazoles for use as CBI modulators
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
GB2454290B (en) Novel serotonergic modulators
GB0817576D0 (en) Calcium ion channel modulators & uses thereof
ZA201100068B (en) Calcium ion channel modulators & uses thereof
HK1138731A (en) Substituted 1, 3-dioxanes useful as ppar modulators
GB2457967B (en) Modulation scheme
HK1155153A (en) 1, 2 disubstituted heterocyclic compounds
AU2008903503A0 (en) The unique block
HK1137997A (en) Sirtuin modulating imidazothiazole compounds
HK1162493A (en) New compounds 578
AU2006902902A0 (en) Immunocytotoxity Modulating Composition
HK1152524A (en) Substituted pyrimidin-5-carboxamides 281
AU2007903365A0 (en) Refrigderator seals